e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
TB treatment: new drugs and drug resistance
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Myungsun Lee (Seoul, Republic of Korea), Myungsun Lee, Namsoo Rhu, Ji Yeon Lee, Joonsung Joh, Youngran Kim, Ina Jeong
Source:
International Congress 2015 – TB treatment: new drugs and drug resistance
Session:
TB treatment: new drugs and drug resistance
Session type:
Poster Discussion
Number:
3334
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Myungsun Lee (Seoul, Republic of Korea), Myungsun Lee, Namsoo Rhu, Ji Yeon Lee, Joonsung Joh, Youngran Kim, Ina Jeong. Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB). Eur Respir J 2015; 46: Suppl. 59, 3334
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Clinical experience of clofazimine in the treatment of MDR-TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Treatment of TB
Source: Eur Respir Mon 2012; 58: 154-166
Year: 2012
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Treating extensively drug resistant tuberculosis (XDR-TB) in India
Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis
Year: 2008
MDR-TB treatment outcomes in HIV positive patients
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Surgical treatment of multidrug-resistant tuberculosis (MDR TB)
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Year: 2003
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016
Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens
Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept